In a recent article by Erkinjuntti et al, 1 galantamine, an acetylcholinesterase inhibitor, was shown to be effective in the treatment of probable vascular dementia (VaD) and Alzheimer’s disease (AD) ...

Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative ...

Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and ...

A 2026 informational consumer research report examining FocusMax cognitive support marketing claims, ingredient-level research context, proprietary blend transparency, pricing disclosures, and verific ...

Memopezil is at the center of a rapidly growing conversation about cognitive health in 2026, as consumer interest in brain support has reached an all-time high, with search volume for terms like ...

The Adapt Oculus trial is unique in that it includes a patient population often overlooked in clinical trials, patients presenting with ocular myasthenia gravis (MG).

VANCOUVER, British Columbia & GRAPEVINE, Texas, February 25, 2026--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition," "ACI," or the "Company"), a clinical-stage biopharmaceutical company ...

As of December 2024, five Food and Drug Administration (FDA)-approved therapies can treat myasthenia gravis symptoms and may allow partial to complete remission. There is still no cure, but modern ...

ABSTRACT: The present paper is part of publication of the proceedings of the international symposium “Tropical Islands and Biodiversity”. The aim is to place emphasis on natural products from plant ...